Alzheon doses first patient with novel Alzheimer’s drug
The first patient has been dosed in Alzheon’s Phase I trial of its Alzheimer’s drug.
The biopharmaceutical company dosed the patient in ALZ-507, a novel investigational oral drug candidate. The drug has been developed to target upstream amyloid aggregation and inhibit the formation of neurotoxic soluble amyloid oligomers, which are recognised as a key trigger and driver of Alzheimer’s disease pathology.
ALZ-507 also features an APOE4 corrector mechanism of action, potentially augmenting its primary anti-oligomer pharmacological effects. Designed as a next-generation oral treatment for Alzheimer’s disease, ALZ-507 could offer the advantages of once-daily dosing and improved gastrointestinal tolerability.
“Dosing the first subject with ALZ-507 marks years of scientific progress at Alzheon as we deepen our understanding of Alzheimer’s disease biology,” said Martin Tolar, Founder, President and CEO of Alzheon.
“This well-differentiated next-generation Alzheimer’s drug candidate also functions as an APOE4 corrector, strengthening its anti-oligomer properties. ALZ-507 is a major step forward for Alzheon’s precision medicine platform aimed at the prevention of formation of neurotoxic soluble amyloid oligomers.
“With Alzheimer’s disease still representing a critical global unmet medical need, we are committed to work toward bringing to patients novel, safe, and accessible therapies that have the potential to slow disease progression.”
